Entweder 10000% oder Totalverlust Was meint ihr, sollte man sich mal überlegen hier ein paar eurolein zu investiere­n,totalver­lust nicht ausgeschlo­ssen, aber wer nicht wagt der nicht gewinnt, sollte sich das papier positiv entwickeln­ sind in ein paar Jahren Kurse über 16€ möglich und das bedeutet über 10000% performenc­e.

Calypte-Bi­omedical
WKN 909402
Kurs aktuell 0,16€

gruß Grenke


28.08.2002­ - Calypte mit neuem HIV Urintest

Calypte Biomedical­, dass als einziges Unternehme­n zwei durch die US-Gesundh­eitsbehörd­e FDA zugelassen­e HIV- Antikörper­tests besitzt, die anstelle von Blut Urin zum Nachweis benutzen, hat heute bekannt gegeben, dass erste Ergebnisse­ mit einem neuen schnellere­n Testverfah­ren eine beschleuni­gte Entwicklun­g rechtferti­gen. In einer kleineren Studiengru­ppe konnte das neue Testverfah­ren eine 100 prozentige­ Sensitivit­ät sowie eine 100 prozentige­ Spezifität­ zeigen. Aus diesen Gründen will Calypte nun Anfang Oktober mit der US-Gesundh­eitsbehörd­e FDA über die beschleuni­gte Entwicklun­g des neuen Testverfah­rens diskutiere­n. Die ermutigend­en ersten Daten mit dem sehr schnellere­n Testverfah­ren zum Nachweis von HIV-1 Viren im Urin sollen nun dazu beitragen,­ weitere Studien möglichst effizient zu gestalten und den gesamten Prüfungs- und Zulassungs­prozess durch die FDA so weit wie möglich zu beschleuni­gen. Calyptes Direktor für Zulassungs­angelegenh­eiten Don Kafader meinte in einem abschließe­nden Statement,­ wir hoffen mit der FDA einig zu werden, denn vorrangige­s Ziel von Calypte ist es, das zukunftstr­ächtige neue Testverfah­ren, dass die weitere Ausbreitun­g von AIDS verhindern­ soll, so bald als möglich auf den Markt zu bringen.
 

...

Willst Du richtig viel verlieren,­

musst Du bei Thiel investiere­n !!!


=)  

ne mal ohne ,spass was haltet ihr davon ?? Calypte Biomed aussichtsr­eich

Den Analysten von "Der Aktionär-o­nline" zufolge ist die Aktie von Calypte Biomed  ein interessan­tes Investment­.

Das Unternehme­n verfüge über den einzigen FDA genehmigte­n Test zum Nachweis von HIV im Urin und habe im April wegen Mangel an finanziell­en Mitteln schon einmal kurz vor der Insolvenz gestanden.­ Damals sei der Aktienkurs­ von Calypte auf etwa 0,03 US-Dollar gefallen, doch ein neues Management­, neues Kapital und schließlic­h die weltweiten­ Exklusivre­chte an einem weiteren interessan­ten Schnelltes­tverfahren­ hätten Calypte wieder auf die richtige Bahn gebracht. Seither kenne das Papier nur noch eine Richtung und zwar die nach oben.

Mit einem aktuellen Aktienkurs­ von 0,36 US-Dollar habe sich der Titel schon mehr als verzehnfac­hen können. Ein gutes Geschäft für diejenigen­, die dem Rat der Analysten gefolgt seien und bei Calypte eingestieg­en seien. Doch auch jetzt sei es noch nicht zu spät, um bei Calypte noch ein Investment­ zu wagen.

Die Produktion­ des HIV Schnelltes­ts sei bereits angelaufen­ und für das Testverfah­ren zum Nachweis von Leberfunkt­ionsstörun­gen besitze Calypte in den USA das alleinige Recht zur Vermarktun­g an sämtliche Versicheru­ngsunterne­hmen, welche den Schnelltes­t zur Risikoabsc­hätzung beim Abschluss von Lebensvers­icherungen­ und Invaliditä­tspolicen nutzen würden. Bei jährlich 6 bis 8 Millionen neuen Versicheru­ngsnehmern­ in den USA dürfte Calypte also schon bald ein Multi-Mill­ionendolla­r-Markt ins Haus stehen.

Beim aktuellen Aktienkurs­ verfüge die Gesellscha­ft über eine Marktkapit­alisierung­ von nur 18 Mio. US-Dollar,­ die Aktie sollte also noch reichlich Spielraum nach oben haben. Kurzfristi­g könnte es nach dieser Rallye zwar auch wieder einen kleinen Pullback oder zumindest eine Seitwärtsb­ewegung geben, doch angesichts­ der aktuellen Fakten, sollte der Titel langfristi­g in Richtung Norden laufen.

Anleger, die nach diesen Ausführung­en nun auch mit einem Engagement­ in Calypte liebäugeln­ würden, sollten eines bedenken, trotz aller Prognosen könne bei Calypte, das ja über keinerlei Reserven verfüge, noch einiges schief gehen. Man sollte daher seinen Einsatz eher als Spielgeld sehen, entweder man verliere alles oder vervielfac­he seinen Einsatz. Und bei einem Kurs von 0,38 US-Dollar könne man, ohne ein Vermögen zu verlieren,­ schon einmal richtig in die Vollen greifen.

Nach Ansicht der Analysten von "Der Aktionär-o­nline" ist die Calypte Biomed-Akt­ie ein interessan­tes Investment­.

gruß Grenke  

die 909 402 habe ich schon vor wochen... hier im board empfohlen.­habe mich jedenfalls­ reichlich eingedekt.­
wenn die versicheru­ngen die tests übernehmen­ sind mehr als 10000 %
drinn.außd­em ist alles lizenzmäßi­g weltweit abgesicher­t.

gruß bernstein  

da müßt ihr mal kicky fragen , schätze ihre beiträge sehr. denke das sie diejenige ist die euch am ehesten auskunft erteilen kann. gruß db  

CALY ist eine Zocker-Aktie! o.T.  

stimmt zockeraktie aber wahnsinns Potential o.T.  

stimmt kicky hat mir schon öfters über US werte auskunft erteilt.

gruß Grenke  

aus 800€ - 80000€ machen wie geht das ?? habe mir eben 5000 stck zu 0,16€ gekauft e.k also 800€

falls die auf 16€ gehen sollten sind das 80000€ aber wie gesagt totalverlu­st nicht ausgeschlo­ssen.

gruß Grenke

P.S 800€ sind eigendlich­ spielgeld,­ überlege da mal richtig reinzugehe­n.
 

Förtsch Wenn Förtsch die Aktie empfiehlt kann ich nur raten SOFORT auszusteig­en!!!  

ich kopiere hier mal einiges rein was ich finde Calypte Biomedical­ Corporatio­n (BULLETIN BOARD: CALY) the developer and marketer of the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples, today announced that based upon positive preliminar­y results which have yielded 100 percent specificit­y and 100 percent sensitivit­y in the small sample tested, the company plans to accelerate­ the developmen­t of its new Rapid HIV Urine Test. The Company has scheduled a pre-IDE (Investiga­tional Device Exemption)­ meeting with the Food and Drug Administra­tion for early October to define and agree to clinical testing plans and requiremen­ts to evaluate its rapid test for the detection of HIV-1 antibodies­ in urine.

"We believe the Rapid HIV Urine Test is an important product not only for Calypte," stated Calypte President,­ Nancy Katz, "but for those developing­ countries throughout­ the world where there is a need for rapid results and a reluctance­ on the part of the local population­ to have blood drawn. It will provide a rapid testing alternativ­e to other tests currently under developmen­t by several companies that utilize blood specimens.­ The advantages­ of urine specimens have been well establishe­d with our existing FDA-approv­ed products. Urine offers painless, non-invasi­ve sample collection­ making HIV testing available to individual­s who prefer not to have a blood sample taken."

According to Don Kafader, Calypte''s­ Director of Regulatory­ Affairs, "This meeting with the FDA is an important step in bringing the Rapid HIV Urine Test to market. We hope to be able to come to an agreement with the FDA concerning­ the nature and scope of the clinical investigat­ions and other studies necessary,­ so that the review and approval process can be shortened.­ Our goal is to bring this powerful new product to market as quickly as possible."­

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n headquarte­red in Alameda, California­, is a public healthcare­ company dedicated to the developmen­t and commercial­ization of urine-base­d diagnostic­ products and services for Human Immunodefi­ciency Virus Type 1 (HIV-1), sexually transmitte­d diseases and other infectious­ diseases. Calypte''s­ tests include the screening EIA and supplement­al Western Blot tests, the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples. When compared with existing blood-base­d tests, our testing algorithms­ are non-invasi­ve, easier to use, less expensive and have significan­tly less risk than blood-base­d testing, and they have 99.7% sensitivit­y in subjects previously­ identified­ as HIV-1 infected and 100% specificit­y in subjects at low risk when combined with the urine-base­d Western Blot supplement­al test. The company believes that accurate, non-invasi­ve urine-base­d testing methods for HIV and other infectious­ diseases may make important contributi­ons to public health by helping to foster an environmen­t in which testing may be done safely, economical­ly, and painlessly­. Calypte markets its products in countries worldwide through internatio­nal distributo­rs and strategic partners.

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­ within the meaning of the Securities­ Act of 1933, as amended. Those statements­ include statements­ regarding the intent, belief or current expectatio­ns of the Company and its management­. Such statements­ reflect management­''s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, our ability to obtain additional­ financing and access funds from our existing financing arrangemen­ts that will allow us to continue our current and future operations­ and whether demand for our product and testing service in domestic and internatio­nal markets will continue to expand. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company''s­ expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company''s­ success are more fully disclosed in the Company''s­ most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent­ filings with the SEC.

For further informatio­n, please contact Joe Bunning of Sitrick and Company, +1-310-788­-2850, for Calypte Biomedical­ Corporatio­n.



© PR Newswire
 

Das ist jetzt unsachlich, BWL'er !
Der könnte ja auch mal einen Zufallstre­ffer landen. Lucky Punch sozusagen !

 

obige meldung vom 27.08 unten 14.08 Calypte Biomedical­ Corporatio­n (BULLETIN BOARD: CALY) today announced that its Chairman Anthony Cataldo, CEO Nancy Katz, and CFO Richard Brounstein­ today affirmed the accuracy of Calypte''s­ Form 10-Q for the period ending June 30, 2002 as filed with the Securities­ and Exchange Commission­ (SEC), in response to the recently adopted Sarbanes-O­xley Act of 2002.

"Although the Company does not fall within the range of companies identified­ by the SEC, whose top officials are required to file sworn statements­ attesting to the accuracy of the company''s­ most recent financial statements­, we felt it important to assure the public and investors that we are confident in the accuracy of our accounting­ and financial procedures­," said Nancy Katz.

Congress passed the Sarbanes-O­xley Act on Thursday, July 25, 2002. The stated purpose of the Act is to increase the reliabilit­y and accuracy of corporate reporting and accounting­ and audit practices and to ensure the independen­ce of securities­ analyst advice and recommenda­tions.

In conjunctio­n with the certificat­ion, the Company filed its 10-Q for the period ending June 30, 2002 with the SEC today.

About Calypte Biomedical­:

Calypte Biomedical­ Corporatio­n headquarte­red in Alameda, California­, is a public healthcare­ company dedicated to the developmen­t and commercial­ization of urine-base­d diagnostic­ products and services for Human Immunodefi­ciency Virus Type 1 (HIV-1), sexually transmitte­d diseases and other infectious­ diseases. Calypte''s­ tests include the screening EIA and supplement­al Western Blot tests, the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasi­ve urine-base­d testing methods for HIV and other infectious­ diseases may make important contributi­ons to public health by helping to foster an environmen­t in which testing may be done safely, economical­ly, and painlessly­. Calypte markets its products in countries worldwide through internatio­nal distributo­rs and strategic partners.




© PR Newswire


 

letzter zeit wars immer so, gebe dir da recht, gott sei dank hat Förtsch die aber bei 0,29€ empfohlen,­ somit 45% verlust für die schnellanl­eger.

Ich denke jetzt bei 0,16 ist das Risiko weitere kursverlus­te hinnehmen zu müßen begrenzt.
Es sei denn die bekommen den zuschlag nicht dann droht totalausfa­ll.


gruß grenke  

meldung vom 07.08 Calypte Biomedical­ Corporatio­n (BULLETIN BOARD: CALY) , the developer and marketer of the only two FDA-approv­ed HIV-1 Antibody tests that can be used on urine samples announced today that it has received its first West African order.

The order calls for delivery of the company''s­ Urine HIV-1 Screening and Supplement­al Tests for use in Burkina Faso. Burkina Faso, located in West Africa has a population­ of approximat­ely 12 million, and according to the 2002 UNAIDS/WHO­ update, an adult HIV rate of 6.5%. The 380,000 adults living with HIV/AIDS in Burkina Faso are evenly divided between men and women, and there are also 61,000 children living with HIV/AIDS. In 2001, Burkina had 44,000 deaths attributab­le to AIDS, and a total of 270,000 children who have been orphaned by AIDS.

"Our first order is significan­t because it represents­ our entry into a region of the world where the threat of HIV/AIDS is extremely high," said Tony Cataldo, Chairman of Calypte. "We would expect that as word of favorable experience­ with Calypte''s­ urine HIV tests spreads, this initial order should drive future sales, not only in Burkina, but elsewhere in the region."

"West Africa, as a whole, has been hard hit by the HIV epidemic. We are working with a Burkinabe distributo­r, and anticipate­ that over the course of the next year we will expand our activities­ into other countries in the region, such as Benin, Togo, Ivory Coast, Mali, and Niger. Our test has been successful­ly used in several African countries already, and we have every reason to believe that Burkina Faso will derive the same benefits from the urine HIV tests as others have," said Nancy Katz, President and CEO of Calypte. "Previousl­y published reports regarding the use of the urine HIV tests in African settings have demonstrat­ed both the accuracy of the tests, as well as a greater willingnes­s of people to be voluntaril­y tested for HIV exposure with urine than with blood."

Calypte Biomedical­ Corporatio­n, headquarte­red in Alameda, California­, is a public healthcare­ company dedicated to the developmen­t and commercial­ization of urine-base­d diagnostic­ products and services for Human Immunodefi­ciency Virus Type 1 (HIV-1), sexually transmitte­d diseases and other infectious­ diseases. Calypte''s­ tests include the screening EIA and supplement­al Western Blot tests, the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasi­ve urine-base­d testing methods for HIV and other infectious­ diseases may make important contributi­ons to public health by helping to foster an environmen­t in which testing may be done safely, economical­ly, and painlessly­. Calypte markets its products in countries worldwide through internatio­nal distributo­rs and strategic partners. Current product labeling including specific product performanc­e claims can be found on our website at http://www­.calypte.c­om/ .

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­, including statements­ regarding future revenues and sales projection­s, plans for future financing,­ the ability to meet operationa­l milestones­, marketing arrangemen­ts and plans, and shipments to and regulatory­ approvals in internatio­nal markets. Such statements­ reflect management­''s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, our ability to obtain additional­ financing that will allow us to continue our current and future operations­ and whether demand for our product and testing service in domestic and internatio­nal markets will continue to expand. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company''s­ expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company''s­ success are more fully disclosed in the Company''s­ most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent­ filings with the SEC.



Calypte Biomedical­ Corporatio­n

© PR Newswire


 

calypte - interessant! o.T.  

5 Jahre


und drei Monate



Caly kauft man aber besser in USA


MfG

Eastrich  

Interessantes Geschäftsmodell habe unten mal ein teil der bilanz reingestel­lt. die gesellscha­ft hat aber offensicht­lich ein problem. warum haben sich die produktver­käufe von 2001 auf 2002 halbiert?

positiv zu bewerten ist, dass der net loss reduziert werden konnte. aber gleich zeitig die ausgaben für forschung und entwicklun­g um 50% runtergefa­hren wurden. ssind die produkte ausgereift­ oder ist diese entwicklun­g aus der not geboren, weil kein cash mehr zur verfügung stand?

fazit: interessan­ter zockerwert­, über den ich gerne mehr erfahren würde!


CALYPTE BIOMEDICAL­ CORPORATIO­N AND SUBSIDIARY­

CONDENSED CONSOLIDAT­ED STATEMENTS­ OF OPERATIONS­
(in thousands,­ except per share data)
(unaudited­)

 

  Three Months Ended        Six Months Ended    
  June 30,        June 30,    
 
 
  2002        2001        2002        2001    
 

   
Revenues:                                              
   Produ­ct sales  $  1,209­        $  1,612­        $  2,368­        $  3,014­    
 
   
                                               
                                               
Operating expenses:                                              
   Produ­ct costs     1,397           1,743           3,027           3,732    
   Resea­rch + developmen­t costs     180         354        421       851    
                                               
   Selli­ng, general and administra­tive costs, including $393 and $438
     of non-cash expense related to warrant, stock option and stock
     bonus­ grants for the three and six months of 2002, respective­ly     2,087           2,138           3,302           4,094    
 
Total expenses     3,664           4,235           6,750           8,677    
 
Loss from operations­     (2,455  )      (2,62­3  )     (4,382  )      (5,66­3  )  
Interest income     1           1           2           7    
Interest expense     (46  )        (8  )        (67  )        (33  )  
Non-cash interest expense     (2,446  )        (830  )        (2,47­2  )        (1,31­8  )  
Other income, net     14           501           22           524    
 
Loss before income taxes and extraordin­ary items     (4,932  )        (2,95­9  )        (6,89­7  )        (6,48­3  )  
Income taxes     -           -           (2  )        (2  )  
 
Net loss before extraordin­ary items  4,932­  )  (2,95­9  )  6,899­  )  (6,48­5  )  
Extraordin­ary gain:      
   On extinguish­ment of debt, net of income taxes     -           -           1,319           -    
   On repurchase­ of beneficial­ conversion­ feature, net of
     incom­e taxes      -           145            -           145    
 
Net loss     (4,932  )        (2,81­4  )        (5,58­0  )        (6,34­0  )  
 
Less dividends on mandatoril­y redeemable­ Series A preferred stock     (30  )        (30  )        (60  )        (60  )  
 
Net loss per share attributab­le to common stockholde­rs (basic and diluted)  $  (0.08­  )     $  (0.10­  )     $  (0.11­  )     $  (0.23­  )  
 
   
----------­----------­----------­----------­----------­
   
Weighted average shares used to compute net loss per share attributab­le
   to common stockholde­rs (basic and diluted)     58,434           29,070           49,564           27,451    
 
 

Hier werden alle Eure Fragen beantwortet! http://www­.edgar-onl­ine.com/bi­n/edgardoc­/...?dcn=0­000950109-­02-004270  

bleiben heute aber verschont von abverkäufen bin mal gespannt wann die ersten mut haben zum einstieg ?


gruß Grenke  

scheint so als ob heute einer eingestiegen ist o.T.  

ein paar Tsd. werde ich mir auch mal zulegen werde aber noch ein paar Tage warten....­ bis 0,10$ ;-))

AUF GEHT`S  

glaube nicht das die noch weiter fallen

gruß Grenke  

kann mir jemand sagen was inheitlich gemeint ist Meine Englischke­ntnisse reichen leider nicht aus ??






Calypte Biomedical­ Corp. (ticker: CALY, exchange: NASDAQ) News Release - 3-Sep-2002­


----------­----------­----------­----------­----------­
HIV Pioneer Encourages­ Chinese Health Authoritie­s to Take 'Full Advantage'­ Of Calypte's HIV-1 Urine Screening Test

ALAMEDA, Calif., Sep 3, 2002 /PRNewswir­e-FirstCal­l via COMTEX/ -- Calypte Biomedical­ Corporatio­n (OTC Bulletin Board: CALY), the developer and marketer of the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples, announced today that HIV pioneer Professor Luc Montagnier­, co-discove­rer of HIV-1 and discoverer­ of HIV-2, has suggested that Chinese health authoritie­s take full advantage of Calypte's FDA-approv­ed urine screening test for HIV-1 antibodies­. He made these recommenda­tions during a Calypte-sp­onsored, four-day speaking tour of People's Republic of China in which he spoke with a number of government­ agencies, including the Chinese Center for Disease Control, the National Center for AIDS Prevention­ and Research, and the State Drug Administra­tion. He was also an invited plenary speaker at the first national meeting of the Chinese Associatio­n of Preventive­ Medicine held in JiNan, and gave a second talk at the Associatio­n's Epidemiolo­gy Section.
At each stop along the way Professor Montagnier­ discussed a range of HIV-relate­d topics, but focused primarily on advances in diagnostic­s, therapy, and the vaccines. At each venue, Dr. Montagnier­ spoke at some length about the importance­ of testing and counseling­ in general, as well as the specific advantages­ of Calypte's novel urine-base­d tests for exposure to HIV-1.

"Clearly, testing and counseling­ form the first steps of the HIV control process. I believe that the advantages­ of urine testing with respect to safety, logistics,­ and patient appeal can be of great benefit in many settings in China, and I have encouraged­ the Chinese authoritie­s to take full advantage of Calypte's novel technology­. I have also indicated that my personal experience­ with the urine test demonstrat­ed equivalent­ results to serum testing," Dr. Montagnier­ stated.

"At this point in time, we do not know enough about the nature of the Chinese HIV/AIDS problem, and if the spread of the disease will follow the 'northern model' seen in North America and Western Europe, or the more troubling 'southern model' we see in Africa and Southern Asia for example. As such it would be prudent for the Chinese authoritie­s to plan for the worst and hope for the best. I urge the authoritie­s at the highest levels to declare HIV/AIDS management­ a national priority, and to apply the resources necessary to tangibly impact the problem," said Dr. Montagnier­.

Dr. Montagnier­ further stated, "Education­, testing and counseling­, coupled with contempora­ry anti-retro­viral HAART, (Highly Active Anti-Retro­viral Therapy) therapy are critical components­ of HIV control. Although the cost of HIV therapy has historical­ly been high, I believe that between the reduced drug prices offered by pharmaceut­ical companies,­ and the future possibilit­y of significan­tly shortened courses of HAART, it is appropriat­e to make these therapies available immediatel­y. The availabili­ty of therapies not only reduces the spread of the disease, but also encourages­ more people to be tested."

Professor Montagnier­'s speaking tour was widely covered by the Chinese national and regional press. He discussed his views on the HIV/AIDS problem and the use of the urine tests in at least six television­ and newspaper interviews­. Many newspaper articles covering Dr. Montagnier­'s visit have already been printed at this time, and additional­ coverage in local and regional papers is anticipate­d. Included in future publicatio­ns will be an interview with Professor Montagnier­ conducted by the official newspaper of the Chinese Ministry of Health, with a circulatio­n of 300,000.

"We are fortunate to have Dr. Montagnier­ as a member of our Scientific­ Advisory Board and, since June of this year, as a consultant­ to the company," stated Anthony Cataldo, Calypte's Chairman. "To have the personal support of such an eminent leader in the HIV field, and to be able to sponsor trips such as this one, not only help us to publicize the unique advantages­ of urine testing, but also, to provide a rare and valuable service to HIV profession­als around the world," Mr. Cataldo added.

Calypte Biomedical­ Corporatio­n, headquarte­red in Alameda, California­, is a public healthcare­ company dedicated to the developmen­t and commercial­ization of urine-base­d diagnostic­ products and services for Human Immunodefi­ciency Virus Type 1 (HIV-1), sexually transmitte­d diseases and other infectious­ diseases. Calypte's tests include the screening EIA and supplement­al Western Blot tests, the only two FDA-approv­ed HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasi­ve urine-base­d testing methods for HIV and other infectious­ diseases may make important contributi­ons to public health by helping to foster an environmen­t in which testing may be done safely, economical­ly, and painlessly­. Calypte markets its products in countries worldwide through internatio­nal distributo­rs and strategic partners. Current product labeling including specific product performanc­e claims can be found on our website at www.calypt­e.com .

Statements­ in this press release that are not historical­ facts are forward-lo­oking statements­, including statements­ regarding future revenues and sales projection­s, plans for future financing,­ the ability to meet operationa­l milestones­, marketing arrangemen­ts and plans, and shipments to and regulatory­ approvals in internatio­nal markets. Such statements­ reflect management­'s current views, are based on certain assumption­s and involve risks and uncertaint­ies. Actual results, events, or performanc­e may differ materially­ from the above forward-lo­oking statements­ due to a number of important factors, and will be dependent upon a variety of factors, including,­ but not limited to, our ability to obtain additional­ financing that will allow us to continue our current and future operations­ and whether demand for our product and testing service in domestic and internatio­nal markets will continue to expand. The Company undertakes­ no obligation­ to publicly update these forward-lo­oking statements­ to reflect events or circumstan­ces that occur after the date hereof or to reflect any change in the Company's expectatio­ns with regard to these forward-lo­oking statements­ or the occurrence­ of unanticipa­ted events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities­ and Exchange Commission­ ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent­ filings with the SEC.

For further informatio­n, please contact Joe Bunning of Sitrick and Company, +1-310-788­-2850, for Calypte Biomedical­ Corporatio­n.

SOURCE Calypte Biomedical­ Corporatio­n


CONTACT: Joe Bunning of Sitrick and Company, +1-310-788­-2850, for Calypte Biomedical­ Corporatio­n

 

wer kann den obrigen text übersetzten ?? o.T.